MXPA02012896A - Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. - Google Patents
Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos.Info
- Publication number
- MXPA02012896A MXPA02012896A MXPA02012896A MXPA02012896A MXPA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A MX PA02012896 A MXPA02012896 A MX PA02012896A
- Authority
- MX
- Mexico
- Prior art keywords
- statins
- combinations
- estrogenic agents
- estrogens
- optionally
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21609600P | 2000-07-06 | 2000-07-06 | |
| US21618400P | 2000-07-06 | 2000-07-06 | |
| PCT/US2001/021085 WO2002003977A2 (en) | 2000-07-06 | 2001-06-29 | Combinations of statins, estrogenic agents and optionally estrogens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02012896A true MXPA02012896A (es) | 2003-10-24 |
Family
ID=26910656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02012896A MXPA02012896A (es) | 2000-07-06 | 2001-06-29 | Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1359940A2 (es) |
| JP (1) | JP2004502731A (es) |
| CN (1) | CN1468110A (es) |
| AU (1) | AU2001271785A1 (es) |
| BR (1) | BR0112365A (es) |
| CA (1) | CA2414060A1 (es) |
| MX (1) | MXPA02012896A (es) |
| WO (1) | WO2002003977A2 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006504409A (ja) | 2002-07-24 | 2006-02-09 | チルドレンズ ホスピタル メディカル センター | 鏡像異性のエクオールを含有する組成物および製品、およびその製造方法 |
| US8668914B2 (en) | 2002-07-24 | 2014-03-11 | Brigham Young University | Use of equol for treating skin diseases |
| AU2003286781B2 (en) | 2002-10-29 | 2009-05-21 | Brigham Young University | Use of equol for treating androgen mediated diseases |
| US8580846B2 (en) | 2002-10-29 | 2013-11-12 | Brigham Young University | Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| BR112018006121B1 (pt) | 2015-10-01 | 2024-01-23 | Olema Pharmaceuticals, Inc | COMPOSTOS DE TETRA-HIDRO-1H-PIRIDO[3,4-b]INDOL, COMPOSIÇÕES COMPREENDENDO OS REFERIDOS COMPOSTOS E USOS DOS MESMOS |
| HRP20221462T1 (hr) | 2015-12-09 | 2023-01-20 | The Board Of Trustees Of The University Of Illinois | Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| MX2019000200A (es) | 2016-07-01 | 2019-09-26 | G1 Therapeutics Inc | Agentes antiproliferativos basados en pirimidina. |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| EP3565558B1 (en) | 2017-01-06 | 2023-12-06 | G1 Therapeutics, Inc. | Combination therapy with a serd compound and a cdk4/6 inhibitor for the treatment of cancer |
| TW201835064A (zh) | 2017-02-10 | 2018-10-01 | 美商G1治療公司 | 苯并噻吩雌激素受體調節劑 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP3645001B1 (en) | 2017-06-29 | 2024-07-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN DEGRADATION |
| WO2021007146A1 (en) | 2019-07-07 | 2021-01-14 | Olema Pharmaceuticals, Inc. | Regimens of estrogen receptor antagonists |
| PE20221724A1 (es) | 2019-12-20 | 2022-11-04 | C4 Therapeutics Inc | Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr) |
| KR20220166797A (ko) | 2020-03-05 | 2022-12-19 | 씨4 테라퓨틱스, 인코포레이티드 | Brd9의 표적화된 분해를 위한 화합물 |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| EP4565585A1 (en) | 2022-08-03 | 2025-06-11 | Bristol-Myers Squibb Company | Compounds for modulating ret protein |
| KR20250116017A (ko) | 2022-11-04 | 2025-07-31 | 브리스톨-마이어스 스큅 컴퍼니 | Ret-ldd 단백질 억제제 |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3894299A (en) * | 1998-05-15 | 1999-12-06 | American Home Products Corporation | Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| GEP20033079B (en) * | 1998-05-15 | 2003-10-27 | Wyeth Corp | Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency |
-
2001
- 2001-06-29 CN CNA018150896A patent/CN1468110A/zh active Pending
- 2001-06-29 AU AU2001271785A patent/AU2001271785A1/en not_active Abandoned
- 2001-06-29 CA CA002414060A patent/CA2414060A1/en not_active Abandoned
- 2001-06-29 BR BR0112365-3A patent/BR0112365A/pt not_active IP Right Cessation
- 2001-06-29 EP EP01950826A patent/EP1359940A2/en not_active Withdrawn
- 2001-06-29 JP JP2002508432A patent/JP2004502731A/ja active Pending
- 2001-06-29 WO PCT/US2001/021085 patent/WO2002003977A2/en not_active Application Discontinuation
- 2001-06-29 MX MXPA02012896A patent/MXPA02012896A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002003977A3 (en) | 2003-09-04 |
| BR0112365A (pt) | 2003-05-13 |
| CN1468110A (zh) | 2004-01-14 |
| AU2001271785A1 (en) | 2002-01-21 |
| JP2004502731A (ja) | 2004-01-29 |
| WO2002003977A2 (en) | 2002-01-17 |
| CA2414060A1 (en) | 2002-01-17 |
| EP1359940A2 (en) | 2003-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA02012896A (es) | Combinaciones de estatinas, agentes estrogenicos y opcionalmente estrogenos. | |
| MXPA02012897A (es) | Combinaciones de bisfosfonatos, agentes estrigenicos y opcionalmente estrogenos. | |
| AU5208401A (en) | 3-nitrogen-6,7-dioxygen steroids and uses related thereto | |
| MXPA02012891A (es) | Composiciones farmaceuticas de agentes estrogenicos. | |
| MXPA03000499A (es) | Sistema y metodo de electrocardiografia inalambrica. | |
| ZA200203316B (en) | New use and novel n-azabicyclo-amide derivatives. | |
| MXPA03005445A (es) | Barra colectora 12c para aislar los circuitos integrados seleccionados para una comunicacion rapida de barra colectora 12c. | |
| ZA200204165B (en) | Fulvestrant formulation. | |
| MXPA03002410A (es) | 4-amino-quinazolinas. | |
| MXPA03001983A (es) | Exemestano como agente quimiopreventivo. | |
| ZA200207489B (en) | Apomorphine derivatives and methods for their use. | |
| EG23373A (en) | Process and intermediates. | |
| MXPA03003522A (es) | Panal. | |
| EG23262A (en) | Delta -pyrrolines. | |
| ZA200302014B (en) | Methods and compositions for promoting the maturation of monocytes. | |
| MXPA03001591A (es) | Derivados y analogos de 10-aril-11-h-benzo(b) fluorena para uso medicinal. | |
| MXPA03001877A (es) | 2-guanidin-4-arilquinazolinas. | |
| IL144455A0 (en) | 16-hydroxyestratrienes as selective estrogens | |
| MXPA03002668A (es) | Guanidinas de sulfonilo. | |
| MXPA03005714A (es) | Sulfamidotienopirimidinas. | |
| MXPA03002411A (es) | 4-amino-quinazolinas. | |
| AU2001238027A1 (en) | Cellular coupon system | |
| MXPA03005494A (es) | Benzoilpiridazinas. | |
| MXPA03002521A (es) | Triazol-epotilona. | |
| MXPA01000464A (es) | Composicion. |